Special pathological reporting is necessary in individuals undergoing neoadjuvant systemic therapy (NST). There exist at the very least 5 unique reporting scores with the quality of remission immediately after NST; some of these, however, are only validated for inflammatory breast cancer (e.reconstructive surgical treatment. Determined by meta-anal